NASDAQ:TSHA Taysha Gene Therapies Q2 2026 Earnings Report $5.96 -0.01 (-0.17%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$6.12 +0.16 (+2.65%) As of 07/17/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Taysha Gene Therapies EPS ResultsActual EPSN/AConsensus EPS -$0.11Beat/MissN/AOne Year Ago EPSN/ATaysha Gene Therapies Revenue ResultsActual RevenueN/AExpected Revenue$0.62 millionBeat/MissN/AYoY Revenue GrowthN/ATaysha Gene Therapies Announcement DetailsQuarterQ2 2026Date8/11/2026TimeBefore Market OpensConference Call DateTuesday, August 11, 2026Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Taysha Gene Therapies Earnings HeadlinesTaysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest InJuly 15 at 6:09 PM | finance.yahoo.comTaysha: 'Buy' On Interim Analysis Of TSHA-102 First Half 2027 And Broad Label PotentialJune 30, 2026 | seekingalpha.comThis tiny piece of glass could be bigger than GPUsJensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capital - the firm behind Anthropic and OpenAI - calls it a 'holy grail.' It's smaller than a fingertip and made of glass. Wall Street insider Jason Bodner - who called Nvidia at $4.50 - believes this 'light-speed' device could be bigger for AI than GPUs and is about to launch a new wave of winners. He's sharing his number one stock pick tied to it at no cost.July 18 at 1:00 AM | Brownstone Research (Ad)Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsJune 25, 2026 | finanznachrichten.deTaysha Gene Therapies Announces Major Equity Financing DealJune 25, 2026 | tipranks.comTaysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific MeetingJune 25, 2026 | globenewswire.comSee More Taysha Gene Therapies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Taysha Gene Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Taysha Gene Therapies and other key companies, straight to your email. Email Address About Taysha Gene TherapiesTaysha Gene Therapies (NASDAQ:TSHA) (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders. Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021. The company has secured orphan drug designations from the U.S. Food and Drug Administration for its lead programs and established partnerships to support manufacturing and supply chain needs. With an integrated model that combines in-house research, process development and clinical operations, Taysha aims to accelerate the transition of its candidates from preclinical studies into human trials. Through collaborations with academic institutions, patient advocacy groups and regulatory agencies, Taysha serves both domestic and international patient populations facing devastating genetic disorders. Its clinical trials are conducted across multiple trial sites in North America and Europe, with a focus on leveraging real-world insights to optimize study design and endpoint selection. Led by a management team with deep expertise in gene therapy, translational research and rare disease development, Taysha Gene Therapies is committed to building a broad platform capable of delivering potentially transformative treatments for central nervous system disorders. The company continues to expand its scientific and clinical capabilities to bring durable, one-time gene therapies to patients worldwide.View Taysha Gene Therapies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles TSMC Just Gave AI Chip Bulls Another Reason to Stay ConfidentAehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue GrowthGE Aerospace Faces a Prove-It Moment in Q2 EarningsWhy Abbott Laboratories Stock Is Suddenly Winning Back Wall StreetJ.B. Hunt Stock Could Reach $340 as Trucking Capacity ShrinksPalantir's Wild Ride: Inside the Stock Wall Street Can't Agree OnRevving Up Returns: Big Banks Race Through the Rate Plateau Upcoming Earnings General Motors (7/21/2026)Northrop Grumman (7/21/2026)America Movil (7/21/2026)Alphabet (7/21/2026)Chubb (7/21/2026)Capital One Financial (7/21/2026)Interactive Brokers Group (7/21/2026)Charles Schwab (7/21/2026)Danaher (7/21/2026)Novartis (7/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
